Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Esperion TherapeuticsESPR -0.31%41 3-Year Book Growth Rate is 34.30% as of Mar. 2026. GuruFocus rates ESPR with a GF Score™ of 41/100 and a GF Value™ of $2.28 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 910 Drug Manufacturers companies, Esperion Therapeutics ranks better than 92.64% on this metric.
During the past 3 years, the average Book Value per Share Growth Rate was 34.30% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 18.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Esperion Therapeutics was 34.30% per year. The lowest was -58.50% per year. And the median was -1.20% per year.
Esperion Therapeutics (NAS:ESPR) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Esperion Therapeutics 3-Year Book Growth Rate Related Terms
ESPR vs AMPH, NIKA, BIOA: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Esperion Therapeutics 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Esperion Therapeutics's 3-Year Book Growth Rate falls into.
Esperion Therapeutics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 34.30% mean?
Esperion Therapeutics (ESPR) has a 3-Year Book Growth Rate of 34.30% as of Mar. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Esperion Therapeutics and its competitors. According to the industry distribution chart, Esperion Therapeutics ranks #67 out of 910 companies in the Drug Manufacturers industry, placing it in the top 7.4%.
Is Esperion Therapeutics' 3-Year Book Growth Rate too high?
Esperion Therapeutics' current 3-Year Book Growth Rate is 34.30%. The Drug Manufacturers industry median 3-Year Book Growth Rate is 4.75. Esperion Therapeutics' value of 34.30% is 622.1% above this industry median. Based on the distribution chart, Esperion Therapeutics ranks #67 out of 910 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Esperion Therapeutics has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Esperion Therapeutics' 3-Year Book Growth Rate compare to AMPH and NIKA?
According to the Drug Manufacturers industry distribution chart, Esperion Therapeutics ranks #67 out of 910 companies for 3-Year Book Growth Rate. This places Esperion Therapeutics in the top 7% of its industry — outperforming the majority of peers. The industry median 3-Year Book Growth Rate is 4.75. Esperion Therapeutics' value of 34.30% is 622.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.75, based on 910 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Esperion Therapeutics's current 3-Year Book Growth Rate of 34.30% is 622.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Esperion Therapeutics and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Esperion Therapeutics's current 3-Year Book Growth Rate is 34.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Esperion Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Esperion Therapeutics (ESPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.28, compared to a current price of $3.18 — trading 39.5% above its estimated fair value. The current 3-Year Book Growth Rate is 34.30% and 622.1% above the Drug Manufacturers industry median of 4.75. Esperion Therapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Esperion Therapeutics (ESPR), the current 3-Year Book Growth Rate is 34.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Esperion Therapeutics (ESPR) Overvalued in 2026?
Based on GuruFocus' analysis, Esperion Therapeutics stock appears to be overvalued.
The current stock price of $3.18 is trading 39.5% above its estimated GF Value™ of $2.28.
GuruFocus considers Esperion Therapeutics to be Significantly Overvalued.
Key valuation signals for ESPR:
3-Year Book Growth Rate: 34.30%
GF Value™: $2.28 vs. price of $3.18 (39.5% above fair value)
Industry Position: 622.1% above the Drug Manufacturers median (#67 of 910)
No single metric tells the full story. See the ESPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
41GF Score
Get the complete analysis for ESPR
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESPR has been successfully added to your 
